NCT04109456 - IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

March 16, 2020

Primary Completion Date

June 30, 2025

Study Completion Date

December 30, 2025

Conditions

Metastatic Melanoma

Interventions

DRUG

IN10018

100 mg or 50mg, orally once daily continuously;

DRUG

Cobimetinib

60mg , orally once daily from day 1 to day 21 in a 28-day cycle

BIOLOGICAL

Atezolizumab

biweekly 840 mg dose will be used in this study starting from Cycle 2.

Trial Locations (8)

Columbia University Medical Center, New York

Sylvester Comprehensive Cancer Center., Miami

MD Anderson, Houston

Massachusetts General Hospital, Boston

Dana-Farber Cancer Institute, Boston

St Vincent Hospital Sydney, Sydney

The Alfred Hospital, Melbourne

Linear Clinical Research, Nedlands

All Listed Sponsors

lead

InxMed (Shanghai) Co., Ltd.

INDUSTRY